亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

南京克萊森醫藥化工有限公司  

普瑞巴林中間體,替卡格雷中間體,達比加群酯中間體,羅匹尼羅中間體,利克飛龍中間體,阿扎那韋中間體,拉帕替尼中間體,埃羅替尼中間體,伐侖克林中間體,地瑞那韋中間體,阿替美唑中間體,依替米貝中間體

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:徐罡
  • 電話:025-83172646
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 地瑞那韋中間體160232-08-6
地瑞那韋中間體160232-08-6
單價 面議對比
詢價 暫無
發貨 江蘇南京市付款后3天內
品牌 (1S,2R-(1-芐基-2-羥基-3-(異丁胺)丙基)氨基甲酸叔丁酯
型號 160232-08-6
規格 160232-08-6
過期 長期有效
更新 2012-05-31 16:55
 
詳細信息

Carbamic acid,N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-,1,1-d
imethylethyl ester(1S,2R-(1-芐基-2-羥基-3-(異丁胺)丙基)氨基甲酸叔丁酯  cas 160232-08-6
Name of productCarbamicacid,N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)amino]-
1-(phenylmethyl)propyl]-,1,1-dimethylethyl ester
CAS No160232-08-6
FormulaC19 H32 N2 O3
©2025 南京克萊森醫藥化工有限公司 版權所有   技術支持:化工網   訪問量:9969  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |